Keyphrases
Alzheimer's Disease
72%
Dominantly Inherited Alzheimer's Disease
66%
Clinical Trials
49%
Autosomal Dominant Alzheimer's Disease
46%
Dominantly Inherited Alzheimer Network
34%
Symptom Onset
30%
Mutation Carriers
29%
Gantenerumab
26%
Rate of Change
26%
Solanezumab
20%
Disease Progression
20%
Sporadic Alzheimer's Disease
20%
Non-carriers
17%
Alzheimer's Disease Clinical Trials
17%
Longitudinal Change
17%
Clinical Outcomes
16%
Cerebrospinal Fluid
16%
Dementia
16%
Standardized Uptake Value
15%
Multiple Sclerosis
14%
Treatment Effect
13%
Pittsburgh Compound B
13%
Clinical Dementia Rating
12%
Mixed Model Repeated Measures
12%
Linear Mixed Model
12%
Prevention Trials
11%
DIAN-TU
11%
Placebo
10%
Mini-Mental State Examination
10%
Total tau
10%
Biomarker Changes
10%
Cognitive Decline
10%
Amyloid Burden
10%
Alzheimer's Disease Prevention
10%
Disease-modifying Therapy
9%
Mild Cognitive Impairment
9%
Longitudinal Data
9%
Positron Emission Tomography
9%
Neurodegeneration
9%
Early Alzheimer's Disease
9%
Disease Progression Modeling
9%
Practice Effects
9%
Sample Size Re-estimation
9%
Tau Pathology
9%
Cognitive Impairment
9%
Decline Rate
8%
Progression Rate
8%
Disease Stage
8%
Alzheimer's Disease Biomarkers
8%
Disease-causing mutations
8%
Medicine and Dentistry
Alzheimer's Disease
100%
Amyloid Protein
42%
Biological Marker
34%
Gantenerumab
31%
Clinical Trial
25%
Autosomal Dominant Inheritance
23%
Positron Emission Tomography
21%
Solanezumab
20%
Cerebrospinal Fluid
19%
Tau
17%
Placebo
16%
Diseases
12%
Pittsburgh Compound B
11%
Observational Study
9%
Multiple Sclerosis
9%
Radioactive Tracer
9%
Presenilin 1
9%
Standardized Uptake Value
9%
Disease Exacerbation
8%
Clinical Dementia Rating
7%
Polyethylene Terephthalate
7%
Amyloid Plaque
7%
Neurodegeneration
6%
Neuroinflammation
6%
Carbon 11
6%
Mini-Mental State Examination
6%
Interim Analysis
5%
Prophylaxis
5%
Amyloidosis
5%
Alzheimer's Disease Clinical Trial
5%
Treatment Effect
5%
Comorbidity
5%
